Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, shared a post on X:
“Very happy to share our work now published in ACS Journal Cancer
in collaboration with PanCAN examining real-world implementation of germline genetic testing in pancreatic adenocarcinoma.
Among 1,046 surveyed patients with PDAC: Only 66% were offered germline testing, 69% completed testing. Significant disparities persisted by race, insurance status, and treatment setting. As high as 23% of tested patients harbored pathogenic germline variants, most commonly BRCA2, ATM, and BRCA1.
Importantly, receipt of genetic counseling was associated with higher rates of family cascade testing.
Grateful to all collaborators and PanCAN for supporting this important work.”
Nicholas Hornstein, Assistant Professor at Northwell Health, shared this post, adding:
“Excited to see a paper I was an author on published in collaboration with PanCAN examining real-world implementation of germline testing in pancreatic cancer.
Using a survey of 1,046 patients with PDAC, we found:
- Only 66% were offered germline testing
- Only 69% completed testing
- Major disparities persisted by race, insurance status, and treatment setting.
And this matters. Up to 23% of tested patients harbored pathogenic germline variants, most commonly BRCA2, ATM, and BRCA1.
NGS and germline testing in pancreas cancer are a must, not a maybe. For a meaningful subset of patients, these findings directly impact treatment decisions, clinical trial eligibility, and family counseling. HRD-directed strategies in PDAC are real.
One of the most important parts of this project was working directly with the PanCAN patient network. A great example of how patient advocacy groups can help identify practical, ground-level gaps in care that have significant downstream impact. Another key finding: Receipt of genetic counseling was associated with substantially higher rates of family cascade testing.
A lot of room to do better here.”
Other articles featuring Udhayvir Grewal on OncoDaily.